Monday, 16 Sep 2019

You are here

Risk of Psoriasis Complicating TNF Inhibitor Therapy

A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.

Using the Korea National Health Insurance Claim Data between 2007 and 2016, investigators examined all IBD patients (n = 50,502) to compare 5428 TNFi treated patients with 10,856 matched controls who were TNFI naive. Key findings include:

  • TNFi patient have increased risk for psoriasis - 36.8 per 10 000 person-years compared to the control group (14.5 per 10 000 person-years) (hazard ratio [HR] 2.357, 95% CI: 1.668-3.331).
  • TNFi treated patients also showed a higher risk of Palmoplantar pustulosis (HR 9.355, 95% CI 2.754-31.780) and psoriatic arthritis (HR 2.926, 95% CI 1.640-5.218)
  • Psoriasis risk was roughly the same in Crohn's disease and ulcerative colitis. 
  • The risk for psoriasiform complications was significant for infliximab (psoriasis: HR 2.6, 95% CI 1.8-3.6; palmoplantar pustulosis: HR 9.5, 95% CI 2.8-32.6,; psoriatic arthritis: HR 3.3, 95% CI 1.8-5.8), but nor for adalimumab.
  • Men and younger (10-39 years) patients have significantly higher risks of palmoplantar pustulosis (HR 19.682 [95% CI 3.867-100.169] and HR 14.318 [95% CI 2.915-70.315], respectively).

Mechanisms underlying paradoxical psoriasis are unclear but has been postulated to be due TNFi induction of interferon-a (IFN-a), activation of Th1 and Th17 cells or increased interleukin-10 production.

Psoriasiform diseases may complicate TNFi therapy with the risk of palmoplantar pustulosis being greater in male and younger patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.